Pharmalink Sp. z o.o. secures contract for Isotopic reagents - Successive delivery of 20 doses of Lu177-PSMA-617 (vipivotide-tetraxetan), 1000 MBq/mL injection solution on the day and time of calibration

Poland, May 7 -- Poland based Pharmalink Sp. z o.o. has secured contract from Centrum Onkologii im. Franciszka Lukaszczyka w Bydgoszczy for Isotopic reagents - Successive delivery of 20 doses of Lu177-PSMA-617 (vipivotide-tetraxetan), 1000 MBq/mL injection solution on the day and time of calibration. The value of the contract is worth 193030000 PLN.

Published by HT Digital Content Services with permission from Pivotal Sources....